Zimmer Biomet's share price has been under pressure in recent months due to soft growth, poor cash flows, and higher interest rates. Demographics, the rise of ASCs and technological advancements should be supportive of long-term growth. Zimmer Biomet also expects new product launches to accelerate growth in the second half of 2024.

Geely-owned Zeekr delivered 20,106 cars last month, bringing year-to-date deliveries to 87,870 vehicles. That's slightly more than Nio's 87,426 deliveries for the first six months of 2024.

Private equity firm Blackstone is to sell Japanese drugmaker Alinamin Pharmaceutical to North Asian buyout fund MBK Partners for 350 billion yen ($2.17 billion) the Nikkei newspaper reported on Tuesday.

Berkshire Hathaway stock has risen nearly 4,000,000% since 1965. Warren Buffett remains at the helm, with shares continuing to beat the market.

TOKYO & SAN DIEGO--(BUSINESS WIRE)-- #Altium--Renesas and Altium announced that the Committee on Foreign Investment in the United States completed their investigation of the proposed merger.

Billionaire media mogul Barry Diller is in talks with Paramount's parent firm, National Amusements, for control of Paramount, according to The New York Times, marking the latest bid for Paramount after Skydance Media recently ended merger negotiations with the entertainment conglomerate.

A low valuation and heightened pessimism might attract investors hoping for a successful turnaround. This business keeps reporting declining sales and ongoing net losses.

Apple's (AAPL) upcoming integration of Apple Intelligence software into its smartphone lineup may not be enough to boost sales in the Chinese market in 2025, according to UBS analyst David Vogt. He suggests that competition from Huawei's resurgence in China could slow Apple's regional growth prospects.

Nvidia has become overwhelmingly dependent on the AI market. It faces unpredictable regulatory and competitive challenges.

SAN FRANCISCO and SUZHOU, China , July 1, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announced oral presentation of the latest Phase 1 clinical data of an innovative anti-CLDN18.2 ADC (IBI343) for the treatment of advanced gastric/gastroesophageal junction adenocarcinoma (G/GEJ AC) at the ESMO Gastrointestinal Cancers (ESMO GI) Congress 2024 (NCT05458219). The data demonstrates promising efficacy and a favorable safety profile for IBI343 in patients with advanced gastric cancer whose tumors express CLDN18.2.